4/9/2020  9:59:55 PM Chg. -2.79 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
246.48USD -1.12% 43,405
Turnover: 10.7 mill.
-Bid Size: - -Ask Size: - 63.94 bill.USD 0.00% 53.85

Business description

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
 

Management board & Supervisory board

CEO
Dr. Jeffrey Leiden
Management board
Charles F. Wagner, Jr., Amit K. Sachdev, Carmen Bozic, M.D., Damian Wimot, Dr. David Altshuler, Dr. Reshma Kewalramani, Ludovic Fenaux, Mark Bunnage, Michael J. Parini, Michael Partridge, Mike Tirozzi, Nia Tatsis, Ph.D., Nina Devlin, Paul Negulescu, Stephanie Franklin, Stuart A. Arbuckle
Supervisory board
Dr. Jeffrey Leiden, Bruce I. Sachs, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Dr. William Young, Lloyd Carney, Margaret McGlynn, Terrence C. Kearney, Yuchun Lee
 

Company data

Name: Vertex Pharmaceuticals Inc.
Address: 50 Northern Avenue,Boston, Massachusetts 02210, USA
Phone: +1-617-341-6100
Fax: -
E-mail: -
Internet: www.vrtx.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 66.60%
IPO date: -

Investor relations

Name: Michael Partridge
IR phone: +1-617-444-0585
IR Fax: -
IR e-mail: investorinfo@vrtx.com

Main Shareholders

Freefloat
 
66.60%
T. Rowe Price Associates, Inc.
 
10.00%
FMR LLC
 
8.20%
The Vanguard Group
 
7.60%
BlackRock, Inc.
 
7.60%
Others
 
0.00%